コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 eficial graft-versus-tumor (GVT) activity of allogeneic bone marrow transplantation.
2 MV) is a major threat in patients undergoing allogeneic bone marrow transplantation.
3 ith multiple myeloma who have relapsed after allogeneic bone marrow transplantation.
4 so induce graft-vs-host disease (GVHD) after allogeneic bone marrow transplantation.
5 dministration of liposomal clodronate before allogeneic bone marrow transplantation.
6 was developed as a conditioning regimen for allogeneic bone marrow transplantation.
7 aftment and graft-versus-tumor effects after allogeneic bone marrow transplantation.
8 ease (GVHD) is a critical complication after allogeneic bone marrow transplantation.
9 A minority of patients are cured by allogeneic bone marrow transplantation.
10 c anemia who are not suitable candidates for allogeneic bone marrow transplantation.
11 r T cells in murine parent --> F1 models for allogeneic bone marrow transplantation.
12 st disease (GVHD) is a major complication of allogeneic bone marrow transplantation.
13 t disease (GVHD) is the main complication of allogeneic bone marrow transplantation.
14 e therapies for sickle cell disease, such as allogeneic bone marrow transplantation.
15 he patient subsequently underwent successful allogeneic bone marrow transplantation.
16 ncipal barrier to the more widespread use of allogeneic bone marrow transplantation.
17 r T cells, is the most important toxicity of allogeneic bone marrow transplantation.
18 relapse after remission, and requirement for allogeneic bone marrow transplantation.
19 a nonmyeloablative conditioning regimen and allogeneic bone marrow transplantation.
20 st disease (GVHD) is a major complication of allogeneic bone marrow transplantation.
21 elop chronic graft-versus-host disease after allogeneic bone marrow transplantation.
22 ase (GvHD) is the major limiting toxicity of allogeneic bone marrow transplantation.
23 ues to be a major obstacle to the success of allogeneic bone marrow transplantation.
24 eficial approach to improving the outcome of allogeneic bone marrow transplantation.
25 of choice for patients who do not undergo an allogeneic bone marrow transplantation.
26 ne on recipient antibody responses following allogeneic bone marrow transplantation.
27 phocyte infusion in patients relapsing after allogeneic bone marrow transplantation.
28 st disease (GVHD) is a major complication of allogeneic bone marrow transplantation.
29 tion and 7 Gy of thymic irradiation prior to allogeneic bone marrow transplantation.
30 pon human clinical trials of haplomismatched allogeneic bone marrow transplantation.
31 isease (GVHD), the principal complication of allogeneic bone marrow transplantation.
32 th in infancy unless successfully treated by allogeneic bone marrow transplantation.
33 disease (GVHD) is the major complication of allogeneic bone marrow transplantation.
34 ssive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation.
35 gy of graft-vs-host disease (GVHD) following allogeneic bone marrow transplantation.
36 l reconstitution, is a major complication of allogeneic bone marrow transplantation.
37 mor cells in the setting of nonmyeloablative allogeneic bone marrow transplantation.
38 rom ideal, requiring lifelong transfusion or allogeneic bone marrow transplantation.
39 VHD) mediated by CD4(+) or CD8(+) T cells in allogeneic bone marrow transplantation.
40 T cells can be achieved in a murine model of allogeneic bone marrow transplantation.
41 s of reactive oxygen species (ROS) following allogeneic bone marrow transplantation.
42 t in their ability to prolong survival after allogeneic bone marrow transplantation.
43 t disease (aGVHD) is a major complication of allogeneic bone marrow transplantation.
44 Treatment of the leukemias involved allogeneic bone marrow transplantation.
45 T-cell responses in leukemia patients after allogeneic bone marrow transplantation.
46 and chronic graft-versus-host disease after allogeneic bone-marrow transplantation.
47 e, 2-year EFS was significantly higher after allogeneic bone marrow transplantation (26%) than after
48 into BALB/c recipient mice that had received allogeneic bone marrow transplantation 6 weeks previousl
50 regulatory T cells inhibit lethal GVHD after allogeneic bone marrow transplantation across major hist
54 We administered IL-15 to recipients of an allogeneic bone marrow transplantation (allo BMT) to det
55 syndrome (IPS) is a major complication after allogeneic bone marrow transplantation (allo-BMT) and in
57 factor (KGF), which is given exogenously to allogeneic bone marrow transplantation (allo-BMT) recipi
58 receptor (TCR) pathway for over 1 year after allogeneic bone marrow transplantation (allo-BMT), altho
59 S) is a significant cause of mortality after allogeneic bone marrow transplantation (allo-BMT), and t
66 erapy, autologous transplantation (ABMT), or allogeneic bone marrow transplantation (alloBMT) from ma
69 eletion of donor-reactive host T cells after allogeneic bone marrow transplantation and costimulatory
70 rtant implications for the potential role of allogeneic bone marrow transplantation and gene therapy
71 sease (GVHD) is the major complication after allogeneic bone marrow transplantation and is characteri
72 is a complex condition that can occur after allogeneic bone marrow transplantation and remains a sig
73 ntially lethal complications associated with allogeneic bone marrow transplantation and the frequent
74 disease (GVHD) is a serious complication of allogeneic bone marrow transplantation, and donor T cell
75 disease (cGvHD) is a common complication of allogeneic bone marrow transplantation, and has a major
76 munotherapy has been used for relapses after allogeneic bone marrow transplantation, and it has been
77 mediated by alloreactive donor T cells after allogeneic bone marrow transplantation are limited by a
80 nduced in C57BL/10J mdx (dystrophic) mice by allogeneic bone marrow transplantation (BMT) after condi
84 is a major cause of late mortality following allogeneic bone marrow transplantation (BMT) and is char
85 We evaluated 18,014 patients who underwent allogeneic bone marrow transplantation (BMT) at 235 cent
86 sive timing) were eligible for allocation to allogeneic bone marrow transplantation (BMT) based on ma
89 (GI) graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) can result
92 ine whether concurrent MCMV infection during allogeneic bone marrow transplantation (BMT) could alter
96 leukemia on outcome in 64 patients receiving allogeneic bone marrow transplantation (BMT) for childho
97 major obstacles to successful outcome after allogeneic bone marrow transplantation (BMT) for leukemi
98 success of high-dose chemoradiotherapy with allogeneic bone marrow transplantation (BMT) for lymphom
99 cial step to improve the overall survival of allogeneic bone marrow transplantation (BMT) for patient
100 l responses of the first children to undergo allogeneic bone marrow transplantation (BMT) for severe
101 been advocated to enhance engraftment after allogeneic bone marrow transplantation (BMT) for severe
102 PCR) in a cohort of eight patients receiving allogeneic bone marrow transplantation (BMT) from relate
103 il recently, the only cure for relapse after allogeneic bone marrow transplantation (BMT) has been a
106 id malignancies who experience relapse after allogeneic bone marrow transplantation (BMT) have a poor
107 en these 2 regulatory cell populations after allogeneic bone marrow transplantation (BMT) have not be
109 tients achieving remission were allocated to allogeneic bone marrow transplantation (BMT) if a matche
110 ey determinant of outcome from autologous or allogeneic bone marrow transplantation (BMT) in first CR
113 that respond to host alloantigens following allogeneic bone marrow transplantation (BMT) induce graf
123 dity, and mortality in an established murine allogeneic bone marrow transplantation (BMT) model.
127 of acute GVHD in several well-characterized allogeneic bone marrow transplantation (BMT) models.
130 nemia (SAA) can be successfully treated with allogeneic bone marrow transplantation (BMT) or immunosu
131 (B19) IgG was studied retrospectively in 66 allogeneic bone marrow transplantation (BMT) patients us
132 To test whether patients in remission after allogeneic bone marrow transplantation (BMT) possess a p
133 CRs) in patients with relapsed myeloma after allogeneic bone marrow transplantation (BMT) provides cl
134 major histocompatibility complex-mismatched allogeneic bone marrow transplantation (BMT) reliably in
135 Graft-versus-leukemia (GVL) response after allogeneic bone marrow transplantation (BMT) represents
136 b, administered immediately following murine allogeneic bone marrow transplantation (BMT) resulted in
137 emonstrate in murine and human recipients of allogeneic bone marrow transplantation (BMT) that intest
138 HD) is a severe and frequent complication of allogeneic bone marrow transplantation (BMT) that involv
139 t disease (cGVHD) is a major complication of allogeneic bone marrow transplantation (BMT) the immunop
140 th acute gastrointestinal GVHD who underwent allogeneic bone marrow transplantation (BMT) were compar
141 ere registered on the trial but proceeded to allogeneic bone marrow transplantation (BMT) without ran
142 tion that prevents successful outcomes after allogeneic bone marrow transplantation (BMT), an effecti
143 major obstacles to successful outcomes after allogeneic bone marrow transplantation (BMT), an effecti
144 ts who entered CR, 11 subsequently underwent allogeneic bone marrow transplantation (BMT), and 40 und
145 Noninfectious lung injury is common after allogeneic bone marrow transplantation (BMT), but its as
146 to enhance the graft-versus-tumor effect of allogeneic bone marrow transplantation (BMT), but the co
147 ronic myeloid leukemia (CML) relapsing after allogeneic bone marrow transplantation (BMT), but the me
148 lapse is more frequent after autologous than allogeneic bone marrow transplantation (BMT), due in par
149 ease (GvHD) is a major cause of mortality in allogeneic bone marrow transplantation (BMT), for which
150 ), a noninfectious pulmonary complication of allogeneic bone marrow transplantation (BMT), has not be
152 common, life-threatening complication after allogeneic bone marrow transplantation (BMT), particular
153 in using human umbilical cord blood (CB) for allogeneic bone marrow transplantation (BMT), particular
195 major cause of mortality and morbidity after allogeneic bone marrow transplantation, but can be avoid
196 remains a lethal and morbid complication of allogeneic bone marrow transplantation, but GVHD is tigh
197 c graft-versus-host disease (GVHD) following allogeneic bone marrow transplantation, but its biologic
198 onic graft-versus-host disease (cGVHD) after allogeneic bone marrow transplantation, but the mechanis
199 he trafficking pattern of eDCs in mice after allogeneic bone marrow transplantation by using biolumin
201 he induction of graft-versus-tumor activity, allogeneic bone marrow transplantation can lead to long-
202 of hepatitis C virus (HCV) in the setting of allogeneic bone marrow transplantation can occur through
204 ukemia, progression or recurrence of cancer, allogeneic bone marrow transplantation, cardiac arrhythm
205 aft-versus-leukemia effects in recipients of allogeneic bone marrow transplantation, consistent with
206 gh-dose cyclophosphamide therapy followed by allogeneic bone marrow transplantation cures the disease
207 pse of leukemia remains a common event after allogeneic bone marrow transplantation, despite potentia
211 nor CD8(+) T cells recovered on day 42 after allogeneic bone marrow transplantation expressed the phe
212 ounger than 18 years of age who underwent an allogeneic bone marrow transplantation for HL between 19
213 nditioning has precluded the clinical use of allogeneic bone marrow transplantation for many indicati
214 been made to minimize host pre-treatment for allogeneic bone marrow transplantation for tolerance ind
218 h relapsed chronic myelocytic leukemia after allogeneic bone marrow transplantation has been demonstr
224 ainst graft-versus-host disease (GvHD) after allogeneic bone marrow transplantation have been studied
225 Studies of graft-versus-host disease after allogeneic bone marrow transplantation have shown that t
228 clusion, after TLI/ATS host conditioning and allogeneic bone marrow transplantation, host NKT cells c
229 nts with hematologic malignancies undergoing allogeneic bone marrow transplantation; however, associa
230 lastic anaemia can be effectively treated by allogeneic bone-marrow transplantation, immunosuppressio
232 We investigated the risks and benefits of allogeneic bone marrow transplantation in children with
233 ndidates for alternative treatments, such as allogeneic bone marrow transplantation in first remissio
234 also been proven to be of host origin after allogeneic bone marrow transplantation in numerous studi
235 the incidence of hepatic complications after allogeneic bone marrow transplantation in patients who r
236 t-versus-tumor effects can be achieved after allogeneic bone marrow transplantation in patients with
237 ransplant lymphoproliferative disorder after allogeneic bone marrow transplantation in swine but has
238 Here we describe the initial results of allogeneic bone marrow transplantation in three children
239 s could expand the safety and application of allogeneic bone marrow transplantation in treatment of c
241 shown to enhance T cell reconstitution after allogeneic bone marrow transplantation, in part, by expa
242 sed chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation is a clear demons
248 tablishment of donor cell lineages following allogeneic bone marrow transplantation is frequently ass
250 omplete replacement of the immune system via allogeneic bone marrow transplantation is sufficient to
254 phoma prolongs survival, although the use of allogeneic bone marrow transplantation is under investig
256 reconstitution following LHRHa treatment and allogeneic bone marrow transplantation leads to enhanced
258 mismatch of NK receptors and ligands during allogeneic bone marrow transplantation may be used to pr
259 duce cranial blood velocity, suggesting that allogeneic bone marrow transplantation may prevent infar
262 D) against a solid tumor, we established two allogeneic bone marrow transplantation models with a mur
266 Compared with wild-type (WT) recipients of allogeneic bone marrow transplantation, P-selectin(-/-)
268 nclude presence of intracranial mass effect, allogeneic bone marrow transplantation, recurrent or pro
271 These data demonstrate in a murine model for allogeneic bone marrow transplantation that donor T cell
273 t, although host DCs disappear rapidly after allogeneic bone marrow transplantation, they prime donor
276 histocompatibility complex-matched model of allogeneic bone marrow transplantation was employed in w
279 sus-host disease (GVHD) is a complication of allogeneic bone marrow transplantation whereby transplan
280 lls) efficiently increases the resistance to allogeneic bone marrow transplantation while betaGalCer
281 es in a murine model (B10.BR into CBA/J) for allogeneic bone marrow transplantation with major histoc
282 ients with childhood leukaemia who underwent allogeneic bone-marrow transplantation with HLA-matched
283 responses seen in two patients suggest that allogeneic bone-marrow transplantation without myeloabla
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。